Introduction to RGCC’s Tests

Array Comparative Hybridization (aCGH)

• Missing primary origin or Missing Knowledge?
• Identification of the origin of the primary tumor
• Based on DNA Analysis of CTCs/CSCs for detection of chromosomal abnormalities
• Non-invasive (Blood Sample)
• All types of cancer
• Needless interpretation
• Final results in 3-4 weeks
• Example

Conclusion: According to the profile of CGH analysis the higher probability for the place of origin of the malignancy is the organ of ovaries.

Oncocount

Q: Are there any CTCs present?
A: Use Oncocount

• Purpose: Detection and measurement of CTCs in peripheral blood
• Diagnostic Tool - Presence of malignant cells or not
• Follow up tool – Monitor early relapse
• For both hematologic and solid tumors
• Very low Limit of Detection (can detect rare events)
• Requirements: 7-10 ml of whole (peripheral) blood in RGCC tube

Oncocount sample report

• Both solid tumors and hematologic
  malignancies
• Ideally negative results
• Ideally negative expression
  

Oncotrace

Q: Where do detected CTCs come from?
A: Use Oncotrace

• Purpose: CTC number and immunophenotype for specific types of malignancies.
• Diagnostic tool - Determine tissue of origin / Primary Tumor
• Follow up tool - Control the risk of relapse and monitor the patient’s status during and after treatment
• For both hematologic and solid tumors.
• Requirements: 7-10 ml of whole (peripheral) blood in RGCC tube

Markers used in Oncotrace Diagnosis

Hematologic origin (CD45+)

• B cell origin (CD19)
• Hodgkin lymphoma (CD30)

Solid tumors (CD45-)

• Lung neuroendocrine tumor (CD19)
• Sarcoma (CD34, CD99)
• Melanoma (CD63)
• Epithelial origin (EpCam, CK)
• Breast (MUC-1)
• Prostate (PSMA)
• Renal (VHL mut)

Markers for solid cancer prognosis:

• OKT 3/4 – resistance/recurrence
• SOX2 – resistance/recurrence
• C-met – risk of metastasis
• CD133 – risk of metastasis
• CD44 – risk of metastasis
• Nanog – risk of metastasis

Markers for hematologic cancer prognosis:

• CD34 - tumor initiating cell
• CD19 - B cell origin
• CD30 - Hodgkin’s lymphoma

Oncotrace sample report

• Phenotype ALWAYS prevails over numbers
  

Oncotrail

• Once tumor site is determined, then Oncotrail may be used
• Oncotrail provides information about CTC number and immunophenotype for specific types of malignancies
• Suitable tool for follow up
• Requirements: 10 ml of whole (peripheral) blood in RGCC tube
• Breast Oncotrail
• Colon Oncotrail
• GI Oncotrail
• Lung Oncotrail
• Melanoma Oncotrail
• Prostate Oncotrail
• Sarcoma Oncotrail

Oncotrail sample report

Onconomics

Q. Which is the most effective treatment?
A. Use Onconomics

Effect of specific anti-cancer drugs and targeted therapies on CTCs of individual patient
Both solid tumors and hematological malignancies

• Molecular techniques: epigenetic analysis
• Cellular techniques: viability assays
• Requirements: 15-25 ml of whole (peripheral) blood in RGCC tube

Onconomics sample report

• Alkylating agents
• Topoisomerases I & II
• Nucleoside analogues
• Nucleus spindle stabilizers
• Resistance factors
• Tumor related genes
• Small molecule weight molecules
  

Onconomics Extracts

Q. Which is the most effective natural substance?
A. Use Onconomics Extracts

Efficacy of natural biological substances or extracts on CTCs of individual patient.

• Direct anti-cancer effect: Apoptotic pathways
• Immune stimulation: Release of cytokines
• Inhibition of proliferative signals: Growth factor Receptors, signal transduction

Both solid tumors and hematological malignancies
Requirements: 15-25 ml of whole (peripheral) blood in RGCC tube

Onconomics Extracts sample report

Onconomics Plus

Q. Which is the most effective treatment AND natural substance?
A. Use Onconomics Plus

Onconomics + Onconomics Extracts

Identification of the most effective treatment option, for each patient specifically
Apart from cytotoxic drugs, incorporates also Natural Substances

Requirements: 15-25 ml of whole (peripheral) blood in RGCC tube

Onconomics Plus sample report

ChemoSNiP

The reason people vary in their responses to drug treatments lies in the genetic differences, or variation, between them.

• Used to study How patient’s genome affects response to drugs
• Based on Molecular Biology techniques
• Blood or Swab sample
• Response level of basic metabolism enzymes (CYP2D6, GSTP1, NAT2, etc.)
• Wide range of chemotherapeutic drugs (alkylating agents, antimetabolites, topoisomerase inhibitors, spindle poisons etc.)

Metastat

Living with the unknown

“I feel like if I knew my exact chances of the cancer coming back, I could deal with it. But when I ask my doctor, he gives me a range of statistics over a number of years. I can’t live like this. I need more specifics.”

• Whether a secondary cancerous tumour is likely to develop and its potential location
• CTCs have potential to spread
• Markers vary according to the new metastatic site
• Markers for
• General metastasis
  • Lung metastasis
  • Brain metastasis
  • Liver metastasis
  • Bones metastasis

Immune-frame

Q. How can we assess immune function?
A. Use immune-frame

• Development of cachexia
• Presence and stimulation of DCs
• Specific Humoral or Cellular Immunity
• Non-specific cellular immunity
• Immunosuppressive mechanism
• Requirements: 15-25 ml of whole (peripheral) blood in RGCC tube

Immune-frame sample report

RGCC CAMBISeq

• Beneficial Mutations for cancer treatment?
  
• Response to targeted therapy / immunotherapy
• Cancer Analysis, Mutational, Burden and Instability, Sequencing
• Next Generation Sequencing (NGS)
• Analysis of both DNA and RNA
• Any type of cancer
• High coverage

CefSeq

• Fishing mutations from fragments
  
• Prediction of response to targeted therapy, based on study of circulating- free DNA / circulating-tumor DNA (ctDNA)
• Next Generation Sequencing
• High coverage

Conclusion

RGCC focuses on study of CTCs/CSCs and through our tests we can provide useful information about

• Detection or the Primary Origin of Tumor,
• Treatment efficacy
• Disease Prognosis
• Metabolism of drugs

Different therapies are provided, depending on each condition